Anticipated effects of burosumab treatment on long-term clinical sequelae in XLH: expert perspectives

X-linked hypophosphatemia (XLH) is a rare, progressive, genetic disease with multisystem impact that typically begins to manifest in early childhood. Two treatment options exist: oral phosphate in combination with active vitamin D (“conventional therapy”) and a fully human monoclonal anti-FGF23 anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Seefried, Lothar, Duplan, Martin Biosse, Briot, Karine, Collins, Michael T., Evans, Rachel, Florenzano, Pablo, Hawkins, Neil, Javaid, Muhammad Kassim, Lachmann, Robin, Ward, Leanne M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400326/
https://www.ncbi.nlm.nih.gov/pubmed/37547321
http://dx.doi.org/10.3389/fendo.2023.1211426

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400326/
https://www.ncbi.nlm.nih.gov/pubmed/37547321
http://dx.doi.org/10.3389/fendo.2023.1211426

Ejemplares similares